Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 259.91
HEB's Cash to Debt is ranked higher than
74% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. HEB: 259.91 )
HEB' s 10-Year Cash to Debt Range
Min: 2.31   Max: No Debt
Current: 259.91

Equity to Asset 0.92
HEB's Equity to Asset is ranked higher than
94% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. HEB: 0.92 )
HEB' s 10-Year Equity to Asset Range
Min: 0.35   Max: 0.93
Current: 0.92

0.35
0.93
F-Score: 4
Z-Score: 2.37
M-Score: -2.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -11444.67
HEB's Operating margin (%) is ranked lower than
52% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. HEB: -11444.67 )
HEB' s 10-Year Operating margin (%) Range
Min: -12138.52   Max: -33.33
Current: -11444.67

-12138.52
-33.33
Net-margin (%) -10816.67
HEB's Net-margin (%) is ranked lower than
52% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. HEB: -10816.67 )
HEB' s 10-Year Net-margin (%) Range
Min: -10816.67   Max: -60
Current: -10816.67

-10816.67
-60
ROE (%) -55.38
HEB's ROE (%) is ranked higher than
60% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. HEB: -55.38 )
HEB' s 10-Year ROE (%) Range
Min: -204.52   Max: -12.23
Current: -55.38

-204.52
-12.23
ROA (%) -50.91
HEB's ROA (%) is ranked higher than
59% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. HEB: -50.91 )
HEB' s 10-Year ROA (%) Range
Min: -122.91   Max: -11.05
Current: -50.91

-122.91
-11.05
ROC (Joel Greenblatt) (%) -141.89
HEB's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. HEB: -141.89 )
HEB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4800   Max: -141.89
Current: -141.89

-4800
-141.89
» HEB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

HEB Guru Trades in Q1 2013

Jim Simons 130,300 sh (-60.61%)
» More
Q2 2013

HEB Guru Trades in Q2 2013

Jim Simons 94,000 sh (-27.86%)
» More
Q3 2013

HEB Guru Trades in Q3 2013

Jim Simons 367,200 sh (+290.64%)
» More
Q4 2013

HEB Guru Trades in Q4 2013

Jim Simons 113,000 sh (-69.23%)
» More
» Details

Insider Trades

Latest Guru Trades with HEB



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.90
HEB's P/B is ranked higher than
86% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. HEB: 1.90 )
HEB' s 10-Year P/B Range
Min: 0.67   Max: 20.43
Current: 1.9

0.67
20.43
P/S 346.30
HEB's P/S is ranked lower than
90% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. HEB: 346.30 )
HEB' s 10-Year P/S Range
Min: 0   Max: 367.1
Current: 346.3

0
367.1
EV-to-EBIT 0.50
HEB's EV-to-EBIT is ranked higher than
94% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. HEB: 0.50 )
HEB' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 0.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.60
HEB's Price/Net Cash is ranked higher than
85% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. HEB: 3.60 )
HEB' s 10-Year Price/Net Cash Range
Min: 1.08   Max: 213
Current: 3.6

1.08
213
Price/Net Current Asset Value 3.60
HEB's Price/Net Current Asset Value is ranked higher than
86% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. HEB: 3.60 )
HEB' s 10-Year Price/Net Current Asset Value Range
Min: 1.03   Max: 42.6
Current: 3.6

1.03
42.6
Price/Tangible Book 1.90
HEB's Price/Tangible Book is ranked higher than
90% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. HEB: 1.90 )
HEB' s 10-Year Price/Tangible Book Range
Min: 0.72   Max: 26.63
Current: 1.9

0.72
26.63
Price/Median PS Value 0.40
HEB's Price/Median PS Value is ranked higher than
92% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. HEB: 0.40 )
HEB' s 10-Year Price/Median PS Value Range
Min: 0.57   Max: 13.25
Current: 0.4

0.57
13.25
Earnings Yield (Greenblatt) 194.40
HEB's Earnings Yield (Greenblatt) is ranked higher than
92% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. HEB: 194.40 )
HEB' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 532.3
Current: 194.4

1.6
532.3
Forward Rate of Return (Yacktman) -33.29
HEB's Forward Rate of Return (Yacktman) is ranked higher than
65% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. HEB: -33.29 )
HEB' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -176   Max: -32.9
Current: -33.29

-176
-32.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HXB.Germany
Hemispherx Biopharma, Inc. is a Delaware Corporation founded in the early 1970s. The company is a specialty pharmaceutical company. It is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Since its inception, it has established a foundation of laboratory, pre-clinical and clinical data with respect to the development of natural interferon and nucleic acids to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain chronic diseases. The Company owns and operates a 43,000 sq. ft. manufacturing facility in New Brunswick, NJ that produces Alferon and Ampligen. The Company operates in one segment, which performs research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's primary pharmaceutical product platform consists of its experimental compound, Ampligen, its FDA approved natural interferon product, Alferon N Injection and, its experimental liquid natural interferon for oral administration, Alferon LDO (Low Dose Oral). As of December 31, 2012, the Company had 20 patents worldwide with 70 additional pending patent applications comprising its intellectual property. Its potential competitors are among the largest pharmaceutical companies in the world, are well known to the public and the medical community, and have substantially greater financial resources, product development, and manufacturing and marketing capabilities. The Company is subject to various federal, state and local laws, regulations and recommendations relating to such matters as safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the use of and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its research work.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide